Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abviva has announced that the US Patent and Trademark Office issued a pivotal patent on the core technology used in the company's breast cancer diagnostic test, the Mammastatin Serum Assay or MSA.
Subscribe to our email newsletter
The MSA is developed as a simple blood test that identifies and measures the amount of Mammastatin in women. The MSA is a risk-assessment tool intended to be used by physicians, clinics and hospitals to aid in the early detection of breast cancer and as a broad population based early breast cancer screening test. This new patent signifies the increased importance of the MSA for early breast cancer detection and further strengthens the intellectual property protection of the test.
Doug Lane, president and CEO of Abviva, said: “Abviva has the exclusive option to license the therapeutic uses of Mammastatin from the University of Michigan to develop one or more breast cancer therapeutic drugs.”